D-0690-2021 Class III Terminated
FDA drug recall D-0690-2021 was initiated by Teligent Pharma, Inc. on Jun 22, 2021 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated Jul 3, 2024). Affected quantity: 22,824 tubes.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 28, 2021
- Initiation Date
- Jun 22, 2021
- Termination Date
- Jul 3, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 22,824 tubes
Product description
Erythromycin Topical Gel, 2%, Net Wt. (a) 30 g,(NDC 52565-033-30) (b) 60 g,(NDC 52565-033-60) Rx Only, Manufactured by: Teligent Pharma, Inc. , Buena, NJ 08310,
Reason for recall
Failed Impurities/Degradation Specifications
Distribution pattern
Nationwide
Code information
1) NDC 52565-033-30 Lot 14010, Exp July 2021; 2) NDC 52565-033-60 Lot 13865, Exp June 2021; Lot 14011, Exp July 2021.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0690-2021
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026